Appendix E - National Coverage Determinations Manual / FDG PET for Oncologic Conditions

Why This Topic Matters

The article affects how providers interpret Medicare payment policy for oncologic FDG PET services and how they distinguish covered, non-covered, and research-based use cases. It is important for accurate claims review, coverage verification, and compliance with CMS national policy.

Article Sections

1. General

   Introduces the CMS reconsideration of FDG PET coverage policy and the scope of the review across oncologic indications.

2. Framework

   Describes the updated coverage framework and the effective date for claims under the revised structure.

3. Initial Anti-tumor Treatment Strategy

   Summarizes CMS coverage determinations for initial treatment strategy uses and identifies major exceptions and special circumstances.

4. Subsequent Anti-tumor Treatment Strategy

   Covers CMS policy for later-stage treatment strategy uses, including categories addressed through coverage with evidence development and the research study requirements discussed in the article.

5. Synopsis of New Framework

   Provides an overview table of FDG PET coverage status by tumor type under the revised framework and notes the review date.